Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment ConferencesGlobeNewsWire • 08/19/24
CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap EventAccesswire • 08/15/24
Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy?Zacks Investment Research • 06/07/24
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsGlobeNewsWire • 05/13/24
Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal InfluenzaGlobeNewsWire • 05/01/24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsGlobeNewsWire • 03/28/24
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza AGlobeNewsWire • 03/19/24
Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCapAccesswire • 03/05/24
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza AGlobeNewsWire • 12/06/23
Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West CoastGlobeNewsWire • 11/29/23
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023GlobeNewsWire • 11/27/23
Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West CoastGlobeNewsWire • 11/09/23
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344GlobeNewsWire • 10/31/23
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 09/05/23
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 04/10/23
Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023GlobeNewsWire • 03/22/23
Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day PodcastNewsfile Corp • 01/23/23
Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022GlobeNewsWire • 12/01/22
Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza AGlobeNewsWire • 11/17/22
Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of InfluenzaGlobeNewsWire • 11/01/22
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344GlobeNewsWire • 10/26/22
Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth ConferenceGlobeNewsWire • 10/05/22